- ten23 health® has announced a manufacturing collaboration to support commercialisation of the BD Libertas™ wearable injector for large-volume subcutaneous drug delivery.
- The collaboration combines the BD Libertas™ platform with ten23 health’s process development, aseptic filling, assembly, and quality control services.
ten23 health has announced a manufacturing collaboration to support the commercialisation of the BD Libertas™ wearable injector. The collaboration is intended to offer biopharma companies supply-chain readiness through a fully integrated, ready-to-use solution for subcutaneous delivery of large-volume drugs.
The collaboration includes the BD Libertas™ wearable injector with a 5 ml or 10 ml BD glass cartridge. This is supported by ten23 health’s process development, aseptic filling, assembly, and quality control services. The set-up is designed to allow pharmaceutical partners to use the BD Libertas™ platform alongside ten23 health’s development and contract manufacturing capabilities to advance high-volume subcutaneous treatments towards the clinic and market.
The announcement also highlights ten23 health’s recently introduced Line 0. According to the company, Line 0 allows pharmaceutical customers to test cartridge compatibility, conduct stability studies, and optimise filling and stopper-setting processes under representative conditions without using GMP production. This is positioned as a way to inform scale-up decisions earlier in development.
The BD Libertas™ wearable injector is described as a ready-to-use device for subcutaneous administration of high-dose biologics, with the aim of supporting transitions from intravenous to subcutaneous delivery. By combining BD’s platform technology with ten23 health’s integrated CDMO services, the collaboration seeks to support supply-chain readiness and smoother regulatory pathways.
“Enabling successful patient treatment on behalf of our customers is a key priority for ten23.”
Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer at ten23 health
He added that the company is “happy to expand our collaboration to also include BD Libertas™ Wearable Injector platform,” referencing prior collaboration with BD on the BD iDFill™ solution.
